Algernon Pharmaceuticals completed its clinical trial agreement with Westchester Research Center at Westchester General Hospital in Miami, Florida, for its multinational Phase IIb/III trial of NP-120 (ifenprodil) for COVID-19. The trial is expected to start after July 20.
Algernon is pleased to announce that it has now enrolled 100 patients, which is two thirds of it enrollment target...
The Company has selected and finalized with five clinical sites in Florida, Texas and California for enrollment of patients in the Phase 3..
Algernon has now enrolled 75 patients, which is 50% of its enrollment target, for its multinational Phase 2b/3 human study of NP-120